Impact of novel oncogenic pathways regulated by antitumor miR‐451a in renal cell carcinoma. Issue 4 (9th March 2018)
- Record Type:
- Journal Article
- Title:
- Impact of novel oncogenic pathways regulated by antitumor miR‐451a in renal cell carcinoma. Issue 4 (9th March 2018)
- Main Title:
- Impact of novel oncogenic pathways regulated by antitumor miR‐451a in renal cell carcinoma
- Authors:
- Yamada, Yasutaka
Arai, Takayuki
Sugawara, Sho
Okato, Atsushi
Kato, Mayuko
Kojima, Satoko
Yamazaki, Kazuto
Naya, Yukio
Ichikawa, Tomohiko
Seki, Naohiko - Abstract:
- Abstract : Recent analyses of our microRNA (miRNA) expression signatures obtained from several types of cancer have provided novel information on their molecular pathology. In renal cell carcinoma (RCC), expression of microRNA‐451a ( miR‐451a ) was significantly downregulated in patient specimens and low expression of miR‐451a was significantly associated with poor prognosis of RCC patients ( P = .00305) based on data in The Cancer Genome Atlas. The aims of the present study were to investigate the antitumor roles of miR‐451a and to identify novel oncogenic networks it regulated in RCC cells. Ectopic expression of miR‐451a significantly inhibited cancer cell migration and invasion by RCC cell lines, suggesting that miR‐451a had antitumor roles. To identify oncogenes regulated by miR‐451a in RCC cells, we analyzed genome‐wide gene expression data and examined information in in silico databases. A total of 16 oncogenes and were found to be possible targets of miR‐451a regulation. Interestingly, high expression of 9 genes ( PMM2, CRELD2, CLEC2D, SPC25, BST2, EVL, TBX15, DPYSL3, and NAMPT ) was significantly associated with poor prognosis. In this study, we focused on phosphomannomutase 2 ( PMM2 ), which was the most strongly associated with prognosis. Overexpression of PMM2 was detected in clinical specimens and Spearman's rank test indicated a negative correlation between the expression levels of miR‐451a and PMM2 ( P = .0409). Knockdown of PMM2 in RCC cells inhibited cancerAbstract : Recent analyses of our microRNA (miRNA) expression signatures obtained from several types of cancer have provided novel information on their molecular pathology. In renal cell carcinoma (RCC), expression of microRNA‐451a ( miR‐451a ) was significantly downregulated in patient specimens and low expression of miR‐451a was significantly associated with poor prognosis of RCC patients ( P = .00305) based on data in The Cancer Genome Atlas. The aims of the present study were to investigate the antitumor roles of miR‐451a and to identify novel oncogenic networks it regulated in RCC cells. Ectopic expression of miR‐451a significantly inhibited cancer cell migration and invasion by RCC cell lines, suggesting that miR‐451a had antitumor roles. To identify oncogenes regulated by miR‐451a in RCC cells, we analyzed genome‐wide gene expression data and examined information in in silico databases. A total of 16 oncogenes and were found to be possible targets of miR‐451a regulation. Interestingly, high expression of 9 genes ( PMM2, CRELD2, CLEC2D, SPC25, BST2, EVL, TBX15, DPYSL3, and NAMPT ) was significantly associated with poor prognosis. In this study, we focused on phosphomannomutase 2 ( PMM2 ), which was the most strongly associated with prognosis. Overexpression of PMM2 was detected in clinical specimens and Spearman's rank test indicated a negative correlation between the expression levels of miR‐451a and PMM2 ( P = .0409). Knockdown of PMM2 in RCC cells inhibited cancer cell migration and invasion, indicating overexpression of PMM2 could promote malignancy. Analytic strategies based on antitumor miRNAs is an effective tool for identification of novel pathways of cancer. Abstract : Our data demonstrated that expression of miR‐451a was significantly downregulated in clinical RCC cells and the miRNA acted as a tumor suppressor via targeting of PMM2. High expression of PMM2 was significantly associated with poor prognosis in RCC patients. Elucidation of the pathways mediated by the miR‐451a/PMM2 axis should improve our understanding of oncogenic mechanisms and lead to novel treatment strategies in RCC. … (more)
- Is Part Of:
- Cancer science. Volume 109:Issue 4(2018)
- Journal:
- Cancer science
- Issue:
- Volume 109:Issue 4(2018)
- Issue Display:
- Volume 109, Issue 4 (2018)
- Year:
- 2018
- Volume:
- 109
- Issue:
- 4
- Issue Sort Value:
- 2018-0109-0004-0000
- Page Start:
- 1239
- Page End:
- 1253
- Publication Date:
- 2018-03-09
- Subjects:
- antitumor -- microRNA -- miR‐451a -- PMM2 -- renal cell carcinoma
Cancer -- Periodicals
Neoplasms -- Periodicals
Research -- Periodicals
Electronic journals
616.994005 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=1347-9032;screen=info;ECOIP ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1349-7006 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cas.13526 ↗
- Languages:
- English
- ISSNs:
- 1347-9032
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.603000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 6390.xml